Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:44 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Ph1 Volasertib Plus Romidepsin in R/R PTCL and CTCL
NCT02757248 · Anne Beaven, MD · PHASE1 · withdrawn · last registry update 2016-12-01 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Boehringer Ingelheim is discontinuing their volasertib development program” | – | Registry record, Anne Beaven, MD |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PLK1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2017-11-22Results posted on the registry: Boehringer Ingelheim, BI 6727, IV infusion (NCT01023958)
- 2017-04-05Also stopped (withdrawn): University of Alberta, Volasertib + Idarubicin (NCT02527174)
- 2017-01-27Also stopped (withdrawn): Boehringer Ingelheim, Volasertib (NCT02722135)
- 2016-12-15Also stopped (withdrawn): Northwestern University, Vincristine Sulfate Liposome + Volasertib (NCT02861040)
- 2016-09-20Results posted on the registry: Boehringer Ingelheim, pemetrexed + pemetrexed (NCT00824408)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision